In June 2017, MAPS raised $675,013 in new donations and pledges from 326 supporters. June 1st marked the start of the new Fiscal Year.
MAPS is moving forward with its research on MDMA-assisted psychotherapy for the treatment of PTSD. Phase 3 studies will cost between $25-$35 million for both FDA and European Medicines Agency (EMA) approval. With $12.5 million pledged or in hand, there’s still a funding gap we need to close.
We extend a special thanks to those who so generously supported MAPS last month:
- Adam Wiggins ($50,000)
- Max Kerr ($3,500)
- John Buchanan ($2,500)
- Stephen & Eve Milstein ($1,000)
- Mark Smith ($1,000)
MDMA/PTSD Phase 3 Studies
- Libra Foundation ($600,000 pledged over two years)
MAPS relies on the generosity of individual donors to achieve our mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate